CLINICAL TRIAL

Survey Administration for Carcinoma, Ductal

Recruiting · 18+ · All Sexes · Houston, TX

This study is evaluating whether a screening test for liver fibrosis and cirrhosis can be used in patients seeking usual clinical care.

See full description

About the trial for Carcinoma, Ductal

Eligible Conditions
Liver and Intrahepatic Bile Duct Carcinoma · Carcinoma, Ductal

Treatment Groups

This trial involves 2 different treatments. Survey Administration is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Laboratory Biomarker Analysis
OTHER
Clinical Evaluation
OTHER
Liver Ultrasonographic Elastography
PROCEDURE
Survey Administration
OTHER
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
, not research Must be a new or existing patient of the HOPE clinic to be seen for usual clinical care and not for research. show original
You must be at least 18 years old to purchase this product. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 3 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 3 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Survey Administration will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma, Ductal. Measurement will happen over the course of At baseline.

Positive anti-hepatitis C virus (HCV) test result
AT BASELINE
Will assess positive anti-HCV test result AND either 1) detectable HCV ribonucleic acid, or 2) history of HCV infection and past anti-HCV treatment. Will estimate the prevalence and exact binomial 95% confidence intervals for each of the fibrosis and cirrhosis risk factors examined in this study. For each risk factor, we will first present a cross tabulation of the dichotomous screening test result by the dichotomous gold standard result. To evaluate the performance of each screening method, will calculate point estimates and 95% confidence intervals for the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio.
Positive hepatitis B surface antigen test result
AT BASELINE
The presence of at least one risk factor for hepatitis B virus (HBV) on the screening questionnaire will indicate a positive (versus negative) screening for HBV infection.
Fibroscan result >= F2
UP TO 3 MONTHS
Will estimate the prevalence and exact binomial 95% confidence intervals for each of the fibrosis and cirrhosis risk factors examined in this study. For each risk factor, we will first present a cross tabulation of the dichotomous screening test result by the dichotomous gold standard result. To evaluate the performance of each screening method, will calculate point estimates and 95% confidence intervals for the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio.

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes carcinoma, ductal?

If ductal carcinoma is linked to the exposure to either the occupational factor, endocrine disruptors or hormonal risk factors. These factors might be linked to the abnormal metabolism of DNA repair genes and their expression.

Anonymous Patient Answer

What are common treatments for carcinoma, ductal?

Breast cancer surgery is often used as a treatment for carcinoma, ductal. In a large number of cases, it is utilized as the first step in an attempted curative procedure. This is a very complex field of breast surgery, necessitating an in-depth clinical examination and consideration of multiple surgical options based on the stage of disease at presentation. There are many factors relevant to the outcome of treatment. For certain groups of patients, the benefits can often be offset by the side effect profile of the treatment employed.

Anonymous Patient Answer

Can carcinoma, ductal be cured?

Carcinoma, ductal responds to definitive surgical procedures, with significant tumor and margin clearance. The ability to achieve complete tumor and margin clearance is independent of pTNM stage. This finding supports the concept that complete tumor removal contributes significantly to both oncologic and clinical outcomes.

Anonymous Patient Answer

What are the signs of carcinoma, ductal?

Results from a recent clinical trial demonstrated that patients suffering from carcinoma, ductal, in a symptomatic phase exhibit a range of systemic symptoms. The predominant systemic symptoms experienced by patients were anemia, body weight loss, and low-grade fever, which were correlated with tumour stage.

Anonymous Patient Answer

What is carcinoma, ductal?

Ductal carcinoma is the second-most-common [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer). Ductal carcinoma is a cancer that has a gradual development and is typically discovered by a combination of a pelvic mass, pelvic pain, or abdominal distention. Treatment for ductal carcinoma is a surgical removal of the tumor.

Anonymous Patient Answer

How many people get carcinoma, ductal a year in the United States?

The most common site of neoplasia, breast cancer, accounted for almost 50% of all neoplasms diagnosed. The diagnosis of breast cancer was more common among African Americans than in Caucasians.

Anonymous Patient Answer

What is survey administration?

Patient interviews during a health history or pre-examination for the purpose of making the diagnosis of benign disease appear to be a useful form of cancer screening.

Anonymous Patient Answer

Who should consider clinical trials for carcinoma, ductal?

Clinical trials with a primary goal of treatment of ductal carcinoma do not necessarily improve outcome. However, they can allow patients to choose their treatments to maximize outcome. Clinical trials targeting patients with ductal carcinoma appear to be warranted.

Anonymous Patient Answer

What are the chances of developing carcinoma, ductal?

Both primary sclerosing cholangitis and primary biliary cirrhosis increase the risk of carcinoma in the gallbladder. Women with primary sclerosing cholangitis also have a higher incidence of the development of carcinoma in the colorectum or prostate.

Anonymous Patient Answer

How does survey administration work?

Given that most women would prefer to self-administer a survey, the present study recommends that the self survey be mailed directly to all respondents once they have answered all the required questions through the telephone-based recruitment technique. Further experiments are required to optimize such a strategy for recruiting women using this technique.

Anonymous Patient Answer

What are the latest developments in survey administration for therapeutic use?

In the last years, survey administration has become a useful tool in measuring the quality of services (as an indicator of the health of a population) as well as in assessing the effects of the interventions as well as the quality of the data. Findings from a recent study of the survey should be checked constantly to avoid, at least, some of the drawbacks of a survey. The evaluation of the survey is often problematic for the reason that the data from the survey are from people whose health status is also affected by the survey as well as by other external phenomena of which the health status might be influenced, such as for example, the people's beliefs on health matters or on diseases, or even the health status of the respondents to the survey.

Anonymous Patient Answer

What is the latest research for carcinoma, ductal?

The latest research suggests that there is little evidence supporting the use of hormone replacement therapy as it has not shown to be effective in improving the overall risk of breast cancer, but there is tentative evidence that some estrogen plus progestin treatment may reduce the incidence of breast cancer by 5-12%. The majority (73%, n=11) of women in this study reported that they knew someone with this condition and that it was somewhat or very difficult to find effective treatments for this condition (63%). The average age of diagnosis was 58 years with an average diagnosis by family practitioners in the UK at 47 years. Over the last 10 years, an increase in the prevalence is observed in all of the breast cancer studies.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Ductal by sharing your contact details with the study coordinator.